RESUMEN
The first aim of this study was to evaluate the usefulness of optimized human fecal material in simulating sulforeductase activity in the lower intestine by assessing bacterial degradation of sulindac and sulfinpyrazone, two sulforeductase substrates. The second aim was to evaluate the usefulness of drug degradation half-life generated in simulated colonic bacteria (SCoB) in informing PBPK models. Degradation experiments of sulfinpyrazone and of sulindac in SCoB were performed under anaerobic conditions using recently described methods. For sulfinpyrazone, the abundance of clinical data allowed for construction of a physiologically based pharmacokinetic (PBPK) model and evaluation of luminal degradation clearance determined from SCoB data. For sulindac, the availability of sulindac sulfide and sulindac sulfone standards allowed for evaluating the formation of the main metabolite, sulindac sulfide, during the experiments in SCoB. Both model compounds degraded substantially in SCoB. The PBPK model was able to adequately capture exposure of sulfinpyrazone and its sulfide metabolite in healthy subjects, in ileostomy and/or colectomy subjects, and in healthy subjects pretreated with metoclopramide by implementing degradation half-lives in SCoB to calculate intrinsic colon clearance. Degradation rates of sulindac and formation rates of sulindac sulfide in SCoB were almost identical, in line with in vivo data suggesting the sulindac sulfide is the primary metabolite in the lower intestine. Experiments in SCoB were useful in simulating sulforeductase related bacterial degradation activity in the lower intestine. Degradation half-life calculated from experiments in SCoB is proven useful for informing a predictive PBPK model for sulfinpyrazone.
Asunto(s)
Sulfinpirazona , Sulindac , Bacterias , Humanos , Intestinos , Cinética , Sulfinpirazona/metabolismo , Sulindac/metabolismoRESUMEN
PURPOSE: To develop a model linking in vitro and in vivo erosion of extended release tablets under fasting and postprandial status. METHODS: A nonlinear mixed-effects model was developed from the in vitro erosion profiles of four hydroxypropyl methylcellulose (HPMC) matrix tablets studied under a range of experimental conditions. The model was used to predict in vivo erosion of the HPMC matrix tablets in different locations of the gastrointestinal tract, determined by magnetic marker monitoring. In each gastrointestinal segment the pH was set to physiological values and mechanical stress was estimated in USP2 apparatus rotation speed equivalent. RESULTS: Erosion was best described by a Michaelis-Menten type model. The maximal HPMC release rate (VMAX) was affected by pH, mechanical stress, HPMC and calcium hydrogen phosphate content. The amount of HPMC left at which the release rate is half of VMAX depended on pH and calcium hydrogen phosphate. Mechanical stress was estimated for stomach (39.5 rpm), proximal (93.3 rpm) and distal (31.1 rpm) small intestine and colon (9.99 rpm). CONCLUSIONS: The in silico model accurately predicted the erosion profiles of HPMC matrix tablets under fasting and postprandial status and can be used to facilitate future development of extended release tablets.
Asunto(s)
Preparaciones de Acción Retardada/química , Tracto Gastrointestinal/metabolismo , Derivados de la Hipromelosa/química , Comprimidos/química , Adulto , Fosfatos de Calcio/química , Química Farmacéutica , Colon/metabolismo , Simulación por Computador , Ayuno , Compuestos Férricos/química , Fumaratos/química , Mucosa Gástrica/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Derivados de la Hipromelosa/metabolismo , Intestino Delgado/metabolismo , Masculino , Periodo Posprandial , Solubilidad , Estrés MecánicoRESUMEN
PURPOSE: Lesogaberan, a γ-aminobutyric acid (GABA)B receptor agonist, was developed for the treatment of gastroesophageal reflux disease in patients with a partial response to proton pump inhibitor therapy. A high prevalence of paresthesia was observed in healthy individuals after dosing with lesogaberan in early-phase clinical trials. The aim of this review was to gain further insight into paresthesia caused by lesogaberan by summarizing the relevant preclinical and clinical data. METHODS: This study was a narrative review of the literature and unpublished data. FINDINGS: The occurrence of paresthesia may depend on the route or rate of drug administration; several studies were conducted to test this hypothesis, and formulations were developed to minimize the occurrence of paresthesia. Phase I clinical studies showed that, in healthy individuals, paresthesia occurred soon after administration of lesogaberan in a dose-dependent manner regardless of the route of administration. The occurrence of paresthesia could be decreased by fractionating the dose or reducing the rate of administration. These findings suggest that the initial rate of absorption plays an important part in the development of paresthesia. Modified-release formulations minimize the occurrence of paresthesia while retaining the anti-reflux activity of the drug, as measured by esophageal pH and the number of transient lower esophageal sphincter relaxations. IMPLICATIONS: The development of lesogaberan was halted because the effect on gastroesophageal reflux disease symptoms observed in Phase II studies was not considered clinically meaningful in the target patient population. Nevertheless, it is an example of successful formulation development designed to minimize the occurrence of a compound's adverse effect while retaining its pharmacodynamic action.
Asunto(s)
Agonistas de Receptores de GABA-A/efectos adversos , Parestesia/inducido químicamente , Ácidos Fosfínicos/efectos adversos , Propilaminas/efectos adversos , Agonistas de Receptores de GABA-A/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Humanos , Ácidos Fosfínicos/uso terapéutico , Propilaminas/uso terapéuticoRESUMEN
A clinical study was conducted to validate the in vivo drug release performance of IntelliCap® CR capsules. 12 healthy, male volunteers were administered IntelliCap® CR capsules, filled with metoprolol as a BCS 1 model drug, and programmed to release the drug with 3 different release profiles (2 linear profiles extending over 6h and 14h, respectively, and a pulsed profile with two equal pulses separated by 5h) using a cross-over design. An oral metoprolol solution was included as a reference. Standard bioavailability variables were determined. In vivo drug release-time profiles for the IntelliCap® CR capsules were calculated from the plasma drug concentrations by deconvolution, and they were subsequently compared with the in vitro drug release profiles including assessment of level A in vitro/in vivo correlation (IVIVC). The relative bioavailability for the linear, extended release profiles was about 85% which is similar to other extended release administrations of metoprolol. There was an excellent agreement between the predetermined release profiles and the in vivo release for these two administrations. For IntelliCap® CR capsules programmed to deliver 2 distinct and equal drug pulses, the first pulse was delivered as expected whereas only about half of the second dose was released. Thus, it is concluded that the IntelliCap® system is well suited for the fast and reliable generation of in vivo pharmacokinetic data for extended release drug profiles, e.g. in context of regional drug absorption investigations. For immediate release pulses delivered in the distal GI tract this version of the device appears however less suitable.
Asunto(s)
Sistemas de Liberación de Medicamentos , Tracto Gastrointestinal/metabolismo , Metoprolol/administración & dosificación , Administración Oral , Adolescente , Adulto , Disponibilidad Biológica , Cápsulas , Estudios Cruzados , Liberación de Fármacos , Tránsito Gastrointestinal , Humanos , Masculino , Metoprolol/sangre , Metoprolol/química , Metoprolol/farmacocinética , Persona de Mediana Edad , Adulto JovenRESUMEN
Four different hydrophilic matrix formulations based on hydroxypropyl methylcellulose (HPMC) were investigated for erosion properties in vivo. Three formulations contained a fixed amount of HPMC (40%) with varying proportions of two HPMC grades with different molecular weights (Methocel K100LV and K4M), and a fourth formulation contained a lower amount of the HPMC of lower molecular weight (20%). The effect of food on the in vivo erosion behavior was investigated on two formulations containing different contents of the same HPMC grade. The in vivo erosion behavior and gastrointestinal transit were investigated using magnetic marker monitoring (MMM). The in vitro and in vivo erosion-time profiles show that the erosion was strongly dependent on the composition of the formulation. The formulations containing a larger proportion of high molecular weight HPMC or higher content of HPMC exhibit relatively slower erosion rate and vice versa. In vivo erosion rates were significantly higher under postprandial administration as compared to fasted state administration. No rapid disintegration of any of the formulations (i.e. formulation failure that can potentially cause dose dumping) was observed.
Asunto(s)
Interacciones Alimento-Droga , Derivados de la Hipromelosa/química , Derivados de la Hipromelosa/farmacocinética , Adulto , Dieta Alta en Grasa , Ayuno/metabolismo , Compuestos Férricos/química , Mucosa Gástrica/metabolismo , Tránsito Gastrointestinal , Humanos , Intestino Grueso/metabolismo , Intestino Delgado/metabolismo , Fenómenos Magnéticos , Masculino , Peso Molecular , Periodo Posprandial , Solubilidad , ComprimidosRESUMEN
PURPOSE: To outline and test a new modeling approach for prospective predictions of absorption from newly developed modified release formulations based on in vivo studies of gastro intestinal (GI) transit, drug release and regional absorption for the investigational drug AZD0837. METHODS: This work was a natural extension to the companion article "A semi-mechanistic model to link in vitro and in vivo drug release for modified release formulations". The drug release model governed the amount of substance released in distinct GI regions over time. GI distribution of released drug substance, region specific rate and extent of absorption and the influence of food intake were estimated. The model was informed by magnetic marker monitoring data and data from an intubation study with local administration in colon. RESULTS: Distinctly different absorption properties were characterized for different GI regions. Bioavailability over the gut-wall was estimated to be high in duodenum (70%) compared to the small intestine (25%). Colon was primarily characterized by a very slow rate of absorption. CONCLUSIONS: The established model was largely successful in predicting plasma concentration following administration of three newly developed formulations for which no clinical data had been applied during model building.
Asunto(s)
Amidinas/administración & dosificación , Amidinas/farmacocinética , Antitrombinas/administración & dosificación , Antitrombinas/farmacocinética , Azetidinas/administración & dosificación , Azetidinas/farmacocinética , Preparaciones de Acción Retardada/química , Adulto , Amidinas/sangre , Antitrombinas/sangre , Azetidinas/sangre , Disponibilidad Biológica , Simulación por Computador , Tracto Gastrointestinal/metabolismo , Humanos , Absorción Intestinal , Masculino , Persona de Mediana Edad , Modelos Biológicos , Adulto JovenRESUMEN
PURPOSE: To develop a semi-mechanistic model linking in vitro to in vivo drug release. METHODS: A nonlinear mixed-effects model describing the in vitro drug release for 6 hydrophilic matrix based modified release formulations across different experimental conditions (pH, rotation speed and ionic strength) was developed. It was applied to in vivo observations of drug release and tablet gastro intestinal (GI) position assessed with magnetic marker monitoring (MMM). By combining the MMM observations with literature information on pH and ionic strength along the GI tract, the mechanical stress in different parts of the GI tract could be estimated in units equivalent to rotation speed in the in vitro USP 2 apparatus. RESULTS: The mechanical stress in the upper and lower stomach was estimated to 94 and 134 rpm, respectively. For the small intestine and colon the estimates of mechanical stress was 93 and 38 rpm. Predictions of in vivo drug release including between subject/tablet variability was made for other newly developed formulations based on the drug release model and a model describing tablet GI transit. CONCLUSION: The paper outlines a modeling approach for predicting in vivo behavior from standard in vitro experiments and support formulation development and quality control.
Asunto(s)
Amidinas/administración & dosificación , Antitrombinas/administración & dosificación , Azetidinas/administración & dosificación , Preparaciones de Acción Retardada/química , Tracto Gastrointestinal/metabolismo , Modelos Biológicos , Profármacos/administración & dosificación , Amidinas/farmacocinética , Antitrombinas/farmacocinética , Azetidinas/farmacocinética , Simulación por Computador , Estudios Cruzados , Tracto Gastrointestinal/química , Tránsito Gastrointestinal , Humanos , Derivados de la Hipromelosa , Masculino , Metilcelulosa/análogos & derivados , Metilcelulosa/química , Concentración Osmolar , Profármacos/farmacocinética , Solubilidad , Estrés Mecánico , ComprimidosRESUMEN
PURPOSE: To develop media simulating human colonic fluids (HCFs), to evaluate their use in predicting intracolonic solubility of ketoconazole, danazol and felodipine and to compare solubilities in HCFs with previously determined solubilities in gastric (HGFs) and small intestinal (HIFs) fluids. METHODS: Fasted state simulated colonic fluid (FaSSCoF) and fed state simulated colonic fluid (FeSSCoF) were designed to reflect fluids previously collected from the ascending colon in healthy adults. Solubilities of the three model compounds were determined in HCFs, simulated HCFs, and plain buffers. RESULTS: For ketoconazole, solubilities in FaSSCoF and FeSSCoF were closer than those in the corresponding plain buffers to the solubility in HCFs. For danazol and felodipine, solubilities in FaSSCoF and FeSSCoF predicted solubilities in HCFs. In the fasted state, solubilities of danazol and felodipine in HCFs were higher than or similar to in HGFs or HIFs, while the ketoconazole solubility was lower. In the fed state, solubilities of all three model compounds in HCFs were lower than in HGFs or HIFs. CONCLUSIONS: FaSSCoF and FeSSCoF more closely predict solubility of poorly soluble compounds in HCFs than plain buffers. In most cases, solubility in HCFs differs from those in HGFs and HIFs.
Asunto(s)
Líquidos Corporales/química , Colon Ascendente/metabolismo , Danazol/química , Felodipino/química , Cetoconazol/química , Modelos Biológicos , Adulto , Disponibilidad Biológica , Líquidos Corporales/metabolismo , Tampones (Química) , Estudios Cruzados , Danazol/farmacocinética , Ayuno , Felodipino/farmacocinética , Contenido Digestivo/química , Humanos , Concentración de Iones de Hidrógeno , Absorción Intestinal , Cetoconazol/farmacocinética , Concentración Osmolar , Valor Predictivo de las Pruebas , SolubilidadRESUMEN
The purpose of this work is to evaluate the roles of lecithin and bile salts in a new generation of fasted simulated small intestinal fluid (FaSSIF-II), thus enhancing the closer mimic of simulated fluids to the real human intestinal fluids (HIF) in drug discovery and drug product development. To assess the effects of lecithin in FaSSIF-II, solubility studies were conducted at 37 °C using four media including first generation simulated intestinal fluid (FaSSIF-I), FaSSIF-II, phosphate pH 6.5 buffer, and HIF. A total of 24 model compounds representing a wide range of biopharmaceutic properties were included. The drug solubility values measured in the FaSSIF-II were compared with those in FaSSIF-I, pH 6.5 buffer and HIF. To assess the effects of bile acids, solubility was measured for 4 compounds in the FaSSIF-I containing five different bile acids of various concentrations. The lecithin concentration in the FaSSIF-II is lowered from 0.75 mM to 0.2 mM. The results suggested that the FaSSIF-II is a better medium to reflect HIF, compared with pH 6.5 phosphate buffer and FaSSIF-I. Solubility of neutral compounds including atovaquone, carbamazepine, cyclosporine, danazol, diethylstilbestrol, felodipine, griseofulvin and probucol in FaSSIF-II showed improvement in predicting the in vivo solubility. The relative standard deviation (SD) of solubility measurement in FaSSIF-II is comparable with FaSSIF-I. For the acidic and basic tested compounds, the FaSSIF-II performs similarly to the FaSSIF-I. Experimental results showed that the level of bile salts typically is less than 5 mM under fasted state. Among the five studied bile acids, the conjugation (glycine or taurine) has no impact on the drug solubilization, while there may be a minimal effect of the degree of hydroxylation of the steroid ring system on solubilization. The lecithin concentration of 0.2 mM in FaSSIF-II has been demonstrated to closely represent HIF, for both neutral and ionizable compounds. In the composition of simulated intestinal fluids, the structure of bile acids has minimal effect, providing the flexibility of choosing one bile salt to represent complex in vivo bile acids.
Asunto(s)
Ácidos y Sales Biliares/metabolismo , Ayuno/metabolismo , Intestino Delgado/metabolismo , Lecitinas/metabolismo , Modelos Biológicos , Líquidos Corporales/metabolismo , Química Farmacéutica , Descubrimiento de Drogas , Humanos , Concentración de Iones de Hidrógeno , Absorción Intestinal , Farmacocinética , Solubilidad , Equivalencia TerapéuticaRESUMEN
PURPOSE: To characterize the fluid composition in ascending colon of fasted adults with ulcerative colitis in relapse and in remission with a view to predicting variations on dosage form performance in the lower inflamed gut. METHODS: Twelve patients participated in a two-phase, crossover study. Enrollment to the relapse phase (Phase A) and designation of the remission state for the second colonoscopy (Phase B) were based on Clinical Rachmilewicz Index values. Samples were analyzed for pH and buffer capacity immediately upon collection. After ultracentrifugation, osmolality, surface tension, soluble protein, soluble carbohydrates, and the levels of ten bile acids, seven short-chain fatty acids (SCFAs), three long-chain fatty acids, triglycerides, diglycerides, monoglycerides, phosphatidylcholine, and cholesterol were measured. RESULTS: Total SCFAs are significantly decreased in relapse, but pH remains unaffected. Regardless of remission/relapse status, pH and isobutyric acid levels are lower than in healthy adults. Buffer capacity, osmolality, and soluble protein are higher than in healthy adults. Treatment with prednisolone increases the volume of intracolonic contents. CONCLUSION: Variations in fluid composition of the ascending colon with activity and severity of ulcerative colitis may have an impact on the performance of orally administered products that are targeted to release the therapeutic agent in the colon.
Asunto(s)
Colitis Ulcerosa , Colon Ascendente/patología , Contenido Digestivo/química , Adolescente , Adulto , Colesterol/química , Colitis Ulcerosa/patología , Ácidos Grasos/química , Femenino , Humanos , Concentración de Iones de Hidrógeno , Masculino , Persona de Mediana Edad , Fosfatidilcolinas/química , Recurrencia , Solubilidad , Adulto JovenRESUMEN
In order to improve the predictability of dissolution testing new apparatuses have been proposed that mimic hydrodynamic and mechanical conditions in the gastrointestinal tract. In this study tested were four different nifedipine extended release (ER) formulations using the paddle apparatus and the reciprocating cylinder as pharmacopoeial test devices as well as two newly developed test apparatuses: the rotating beaker apparatus and the dissolution stress test apparatus. Investigated were Adalat OROS in strengths of 30 and 60 mg, and two hydrophilic matrix formulations: 60 mg nifedipine Coral and Nifedipin Sandoz 40 mg retard. The results demonstrate that the dissolution characteristic of the ER tablets is strongly dependent on the applied test conditions. The dosage form related food effects for Coral 60 mg tablets that were previously observed in human bioequivalence studies could be predicted with the two non-compendial dissolution test devices. The dissolution of Sandoz 40 mg tablets was very sensitive to all applied test conditions. The stable drug delivery characteristics of Adalat OROS observed in numerous in vivo studies was also observed in all of the dissolution tests. In conclusion, the present study shows that besides pH dependency the aspect of the mechanical robustness may be an essential factor affecting the dissolution characteristic of hydrogel matrix formulations.
Asunto(s)
Bloqueadores de los Canales de Calcio/química , Nifedipino/química , Bloqueadores de los Canales de Calcio/administración & dosificación , Química Farmacéutica , Preparaciones de Acción Retardada , Nifedipino/administración & dosificación , Solubilidad , Espectrofotometría UltravioletaRESUMEN
PURPOSE: To characterize the contents of the ascending colon in healthy adults under fasting and fed state conditions, with a view to designing in vitro studies to explain/predict dosage form performance in the lower gut. METHODS: Twelve healthy adults participated in a two-phase crossover study. In Phase A, subjects were fasted (water allowed) overnight plus 5 h in the morning prior to colonoscopy (fasted state). In Phase B, subjects were fasted overnight, consumed a standard breakfast (960 kcal) in the morning, and were offered a light lunch 4.5 h later. In this phase, colonoscopy was performed 1 h after lunch (fed state). Volume, pH, and buffer capacity of colonic contents were measured immediately upon collection. After ultracentrifugation, the supernatant was further characterized. RESULTS: Free water content, pH, surface tension, and isobutyrate levels were lower in fed than in fasted subjects. On the other hand, buffer capacity, osmolality, acetate, butyrate, cholate, and chenodeoxycholate levels were higher in fed subjects. Carbohydrate content; protein content; and levels of long chain fatty acids, phosphatidylcholine, and cholesterol were not affected significantly by prandial state. CONCLUSION: Composition of fluids in the ascending colon is affected by feeding. This may affect the performance of products designed to deliver drug to the colon.
Asunto(s)
Colon Ascendente/efectos de los fármacos , Farmacología , Administración Oral , Adulto , Estudios Cruzados , Humanos , Concentración de Iones de Hidrógeno , Proyectos Piloto , Valores de ReferenciaRESUMEN
The synthesis of four sugar-based surfactants derived from glucose and (R)-12-hydroxystearic acid is described. The surfactants have a hydroxy group in the hydrophobic part, which is either free or acylated using acetyl chloride, hexanoyl chloride, or myristoyl chloride. Three of the synthesized surfactants are water-soluble and are evaluated with respect to their CMCs and hemolytic activities. The fourth surfactant has limited water solubility and is not further included in the study. The investigated surfactants are all hemolytic close to their respective CMC indicating that their use in parenteral formulations may be limited. Nevertheless, surfactants having the proposed structure appear as promising alternatives to existing solubilizing agents for pharmaceutical applications.
Asunto(s)
Carbohidratos/síntesis química , Hemólisis/efectos de los fármacos , Tensoactivos/síntesis química , Carbohidratos/farmacología , Química Farmacéutica , Relación Estructura-Actividad , Tensoactivos/farmacologíaRESUMEN
The haemolytic activity of a number of maltopyranoside surfactants was studied. The study included octyl, nonyl, decyl, dodecyl, tetradecyl, cyclohexyl-propyl, cyclohexyl-hexyl, and dimethyl-heptyl maltopyranoside. The in vitro haemolytic activity was determined by employing a static method in which surfactants are added to an erythrocyte suspension and the released haemoglobin is determined. It was found that alkyl maltopyranosides become more haemolytic the longer the alkyl chain. Branching or presence of cyclic groups clearly decreases haemolytic activity, but it also increases the critical micelle concentration. As a result, the cyclic or branched surfactants do not become better solubilizing excipients than the straight-chain surfactants. The most useful surfactant for pharmaceutical applications appears to be tetradecyl maltopyranoside, which is the least haemolytic surfactant relative to its critical micelle concentration.
Asunto(s)
Hemólisis/efectos de los fármacos , Maltosa/análogos & derivados , Maltosa/farmacología , Tensoactivos/farmacología , Adulto , Algoritmos , Secuencia de Carbohidratos , Humanos , Técnicas In Vitro , Maltosa/química , Datos de Secuencia Molecular , Relación Estructura-Actividad , Tensoactivos/químicaRESUMEN
Gastrointestinal motility and transport as well as concomitant food intake are factors that are known to influence pharmacokinetics derived after intake of extended release dosage forms. However, the mechanisms behind these influencing factors are mostly unknown. In this study the gastrointestinal transit and the in vivo drug release of magnetically labelled extended release tablets containing felodipine were monitored together with the drug absorption phase of pharmacokinetics under fasting and fed conditions in six healthy volunteers using Magnetic Marker Monitoring. It was found that the in vivo drug release profiles of the tablets compared well under fasting and fed conditions. However, the plasma concentration profiles were strongly influenced by concomitant food intake. This could be attributed to elongated residence of the tablets in proximal parts of the stomach, resulting in delayed drug absorption and the occurrence of late high plasma peak concentrations. The lag time until the first appearance of felodipine in plasma and the residence time of the tablets in the proximal stomach, were found to be directly correlated. The study shows that increased plasma peak drug concentrations after intake of extended release formulations together with food can be explained by poor mixing in the proximal part of the stomach and are not necessarily due to failure of the formulation to control drug release (dose dumping).
Asunto(s)
Preparaciones de Acción Retardada , Interacciones Alimento-Droga , Mucosa Gástrica/metabolismo , Adulto , Algoritmos , Bloqueadores de los Canales de Calcio/administración & dosificación , Bloqueadores de los Canales de Calcio/sangre , Bloqueadores de los Canales de Calcio/farmacocinética , Colon/metabolismo , Estudios Cruzados , Felodipino/administración & dosificación , Felodipino/sangre , Felodipino/farmacocinética , Femenino , Vaciamiento Gástrico , Tránsito Gastrointestinal/fisiología , Humanos , Magnetismo , Masculino , Solubilidad , Espectrofotometría UltravioletaRESUMEN
The usefulness of sugar surfactants as solubilizing agents was assessed and compared to commercial polyoxyethylene-based surfactants. The sugar surfactants examined comprised of monosaccharides or disaccharides with alkyl chains ranging from C(8) to C(12). Each surfactant was investigated with respect to solubilization capacity for felodipine and haemolytic activity. The haemolytic activity was determined using a static method in which surfactant solutions were added to fresh dog blood. The polyoxyethylene-based surfactants were found to be more suitable as solubilizing agents than the sugar surfactants due to better solubilization capacities combined with lower haemolytic activities. The sugar surfactants caused severe haemolysis below or at the critical micelle concentration, in contrast to the polyoxyethylene-based surfactants that are nonhaemolytic in this concentration range. The structure-related variations in haemolytic activity are probably due to variations in the surfactants partition coefficients for the distribution equilibrium between the aqueous phase and the cell membrane. Longer alkyl chains cause higher haemolytic activity, while larger saccharide groups lower the activity. The clear difference between sugar and polyoxyethylene surfactants, which are considerably less haemolytic, is due to a combination of low critical micelle concentrations and presumably low degrees of partitioning of the latter surfactants into the cell membranes.